Find clinical trials for Breast Cancer in Budapest, Budapest
CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Related conditions:
Breast Cancer trials near Budapest, Budapest, HUN:
-positive / HER2-negative breast cancer which has spread beyond the original tumor and/or to other organs.During this stud...
Phase 3
Budapest, Hungary and 52 other locations
participants with metastatic or locally advanced Hormone Receptor (HR) positive and Human Epidermal Growth Factor Receptor (HER)2-negative breast...
Phase 2
Budapest, Hungary and 31 other locations
The Phase 2 part of the trial will evaluate the efficacy and safety of the various combinations in patients with ER+/HER2- advanced/metastatic breast...
Phase 1, Phase 2
Budapest, Hungary and 115 other locations
To compare and evaluate the efficacy and safety of Liporaxel® solution (oral paclitaxel) and Taxol® (IV paclitaxel) on recurrent or metastatic breast...
Phase 2, Phase 3
Tatabánya, Hungary and 50 other locations
The goal of this clinical trial is to assess the efficacy of DB-1303/BNT323 compared with investigator's choice chemotherapy in terms of progression-...
Phase 3
Budapest, Hungary and 184 other locations
A study to learn about a new medicine called ARV-471 (PF-07850327) in people who have advanced metastatic breast cancer....
Phase 3
Budapest, Hungary and 446 other locations
mg in postmenopausal women with oestrogen receptor positive advanced breast cancer who have failed on a previous endocrine treatmen...
Phase 3
Székesfehérvár, Hungary and 103 other locations
with inoperable or metastatic HR-positive, HER2- negative breast cancer who have been treated with one or two prior lines of...
Phase 3
Budapest, Hungary and 166 other locations
PREcoopERA is a randomized (2:2:1), multicenter, open-label, three-arm (A, B, C), Window-of-Opportunity (WOO) trial to evaluate the activity and safe...
Phase 2
Budapest, Hungary and 43 other locations
PAKT: AZD5363 in Combination With Paclitaxel in Triple-Negative Advanced or Metastatic Breast Cancer
mg twice per day. Capivasertib or placebo could be interrupted for up to 4 weeks for toxicity.Tumor assessments included computed tomograph...
Phase 2
Budapest, Hungary and 45 other locations
Clinical trials
Research sites
Resources
Legal